The Current Status of iPS Cells in Cardiac Research and Their Potential for Tissue Engineering and Regenerative Medicine
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The recent availability of human cardiomyocytes derived from induced pluripotent stem (iPS) cells opens new opportunities to build in vitro models of cardiac disease, screening for new drugs, and patient-specific cardiac therapy. Notably, the use of iPS cells enables studies in the wide pool of genotypes and phenotypes. We describe progress in reprogramming of induced pluripotent stem (iPS) cells towards the cardiac lineage/differentiation. The focus is on challenges of cardiac disease modeling using iPS cells and their potential to produce safe, effective and affordable therapies/applications with the emphasis of cardiac tissue engineering. We also discuss implications of human iPS cells to biological research and some of the future needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196 · cited 2×
“One of the first such reports described the generation of iPS cells from patients with several genetic diseases with complex inheritance patterns [139].”
BackgroundGeneration of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814 · cited 1×
“[32] by the direct delivery of recombinant proteins [32, 33].”
BackgroundCaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism
Splawski, I., Timothy, K. W., Sharpe, L. M., Decher, N., Kumar, P., Bloise, R., Napolitano, C., Schwartz, P. J., Joseph, R. M., Condouris, K., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.011 · Cited by 1,586 · cited 1×
“2 channel (CACNA1C) [145], a malignant multisystem genetic disorder characterized by lethal arrhythmia, congenital heart defects, QT prolongation, ventricular tachycardia, syndactyly, and autism [128, 145].”
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411 · cited 2×
“Most iPS cells derived from human [12, 15, 16, 35, 38, 44, 57, 58] or murine [8, 14, 27, 35, 44, 53, 58, 59] origin.”
BackgroundHuman cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301 · cited 1×
“More recently, multiple groups have independently reported that suppression of the tumor-suppressor gene p53 markedly enhances iPS cells generation [54–56].”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Kattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M., Hotta, A., Ellis, J., & Keller, G. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.008 · Cited by 1,159
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Modelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041 · cited 2×
“Other cardiac diseases, such as short-QT [10, 12] and Brugada syndrome [2, 46], might be studied in a similar fashion using patient-specific iPS cells.”
BackgroundA p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028
Cardiomyocyte Grafting for Cardiac Repair: Graft Cell Death and Anti-Death Strategies
Zhang, M., Methot, D., Poppa, V., Fujio, Y., Walsh, K., & Murry, C. E. (2001) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2001.1367 · Cited by 878 · cited 1×
“Several studies described cell injections into the beating myocardium that have lead to low retention rate (<10 %) in experimental animals [154–156] and intracoronary infusion in patients [157].”
BackgroundDefining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse
Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.02.001 · Cited by 823
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., Navarrete, E. G., Hu, S., Wang, L., Lee, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003552 · Cited by 696 · cited 2×
“The authors investigated patients with LEOPARD syndrome (Lentigines; electrocardiographic abnormalities; ocular hypertelorism; pulmonary valve stenosis; abnormal genitalia; retardation of growth; deafness) which is a rare multiple congenital anomalies condition, mainly characterized by skin, facial and cardiac anomali…”
BackgroundPatient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690 · cited 4×
“organization as compared to cardiomyocytes derived from healthy individuals [122].”
BackgroundResultInfluentialUsing induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome
Yazawa, M., Hsueh, B., Jia, X., Pasca, A. M., Bernstein, J. A., Hallmayer, J., & Dolmetsch, R. E. (2011) · Nature · doi:10.1038/nature09855 · Cited by 677
Induced Pluripotent Stem Cell Generation Using a Single Lentiviral Stem Cell Cassette
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N., & Mostoslavsky, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-1075 · Cited by 676
Growth of engineered human myocardium with mechanical loading and vascular coculture
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., Pabon, L., Reinecke, H., & Murry, C. E. (2011) · Circulation Research · doi:10.1161/circresaha.110.237206 · Cited by 666
Eschenhagen, T., Fink, C., Remmers, U., Scholz, H., Wattchow, J., Weil, J., Zimmermann, W., Dohmen, H. H., Schäfer, H., Bishopric, N., et al. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.8.9240969 · Cited by 636 · cited 1×
“[180] also generated engineered heart tissues from human ES and iPS cells by using collagen [181, 182] and a commercially available FlexCell system.”
MethodA High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C., & Hochedlinger, K. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.003 · Cited by 563
Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells
Zhou, W., & Freed, C. R. (2009) · Stem Cells · doi:10.1002/stem.201 · Cited by 538 · cited 1×
“[25] created murine iPS cells from fibroblasts and liver cells by using non-integrating adenoviruses; afterwards the same result was achieved in human cells [26].”
BackgroundTechnical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411
Matsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr073 · Cited by 389 · cited 2×
“Human cardiac disease models generated so far to test various drugs using cardiomyocytes derived from patient-specific iPS cells recapitulated at least some features of the disease phenotype [84, 124, 125].”
Marbán, E. (2002) · Nature · doi:10.1038/415213a · Cited by 328
Jung, C. B., Moretti, A., Mederos y Schnitzler, M., Iop, L., Storch, U., Bellin, M., Dorn, T., Ruppenthal, S., Pfeiffer, S., Goedel, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100194 · Cited by 327 · cited 4×
“Retrovirus and lentivirus delivery can cause reactivation of the viral vector, after transplantation, resulting in tumors and other abnormalities [39].”
BackgroundInfluentialCho, H.-J., Lee, C.-S., Kwon, Y.-W., Paek, J. S., Lee, S.-H., Hur, J., Lee, E. J., Roh, T.-Y., Chu, I.-S., Leem, S.-H., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269589 · Cited by 239
Disease characterization using LQTS-specific induced pluripotent stem cells
Egashira, T., Yuasa, S., Suzuki, T., Aizawa, Y., Yamakawa, H., Matsuhashi, T., Ohno, Y., Tohyama, S., Okata, S., Seki, T., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs206 · Cited by 178 · cited 2×
“The three most frequently used methods to differentiate human pluripotent stem cells (ES cells and iPS cells) into cardiomyocytes include (please see review in [69]): (1) coculture with mouse visceral endoderm-like (END-2) stromal cells [70–73], (2) spontaneous embryoid body (EB) differentiation in suspension [74–80],…”
BackgroundMethodGermanguz, I., Sedan, O., Zeevi‐Levin, N., Shtrichman, R., Barak, E., Ziskind, A., Eliyahu, S., Meiry, G., Amit, M., Itskovitz‐Eldor, J., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00996.x · Cited by 160
Cited by
Cardiovascular organ-on-a-chip platforms for drug discovery and development
Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., Ferreira, L., & Khademhosseini, A. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0002 · Cited by 161
“Recent developments in stem cell biology have further enabled the use of patient-specific iPSC-derived CMs for generating in vitro models of cardiac disease.(92) These advances may lead to the creation of physiologically and genetically relevant models of cardiac disease for drug discovery and drug toxicity.”
BackgroundApproaching the in vitro clinical trial: engineering organs on chips
Capulli, A. K., Tian, K., Mehandru, N., Bukhta, A., Choudhury, S. F., Suchyta, M., & Parker, K. K. (2014) · Lab on a Chip · doi:10.1039/c4lc00276h · Cited by 111
Taking Systems Medicine to Heart
Trachana, K., Bargaje, R., Glusman, G., Price, N. D., Huang, S., & Hood, L. E. (2018) · Circulation Research · doi:10.1161/circresaha.117.310999 · Cited by 41
Metadata
- Authors
- Martins, A. M., Vunjak-Novakovic, G., & Reis, R. L.
- Venue
- Stem Cell Reviews and Reports
- Published
- 2014-01-15
- Volume
- 10
- Issue
- 2
- Pages
- 177-190
- ISSN
- 1550-8943 (ISSN-L)
- 1558-6804
- OpenAlex
- W2021121983
- Cited by
- 59
- References
- 31
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.